// App-Quantinova.ai

: Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma

Researchers

Presenter

  • Khoan Vu

Principal Investigators

  • James Rubenstein

  • Gabriel N. Mannis

  • Jimmy Hwang

  • Huimin Geng

Medical Centers

  • Hematology/Oncology Division, University of California, San Francisco, San Francisco, CA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, San Francisco, CA

  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Hematological malignancies

  • Primary central nervous system lymphoma

  • Deep vein thrombosis

  • Subdural hematoma

  • CNS lymphoma

  • Brain cancer

  • Venous thrombosis

  • Lymphomas

  • Hematoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Methotrexate

  • Rituximab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved